Get access

EGFR expression in primary squamous cell carcinoma of the thyroid

Authors

  • Jennifer L. Long MD, PhD,

    Corresponding author
    1. Division of Head and Neck Surgery, University of California-Los Angeles, California, U.S.A.
    • Division of Head and Neck Surgery, UCLA, 10833 LeConte Avenue, Room CHS 62-150, Los Angeles, CA 90024
    Search for more papers by this author
  • Ali M. Strocker MD,

    1. and the Department of Pediatric Otolaryngology, Children's Hospital of Los Angeles, Los Angeles, California, U.S.A.
    Search for more papers by this author
  • Marilene B. Wang MD,

    1. Division of Head and Neck Surgery, University of California-Los Angeles, California, U.S.A.
    2. Department of Otolaryngology, West Los Angeles Veteran's Administration Medical Center, Los Angeles, California, U.S.A.
    Search for more papers by this author
  • Keith E. Blackwell MD

    1. Division of Head and Neck Surgery, University of California-Los Angeles, California, U.S.A.
    Search for more papers by this author

  • Presented as a poster at the Triological Society Western Section Meeting, Rancho Las Palmas, California, U.S.A., February 1, 2008.

Abstract

We present the case of a 57-year-old male with primary squamous cell carcinoma of the thyroid (PSCCT). Epidermal growth factor receptor (EGFR) staining was strongly positive. Pharmaceuticals targeting EGFR may provide an additional therapeutic option for this rare disease with extremely poor prognosis. Laryngoscope, 119:89–90, 2009

Ancillary